MetaVia (MTVA US)

MetaVia Inc. operates as a clinical-stage biotechnology company. The Company focuses on developing dual oxyntomodulin (OXM) analog agonist for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). MetaVia serves customers worldwide.